High-dose chlorozotocin in lung cancer: A southwest oncology group phase II study

C. D. Haas; R. L. Stephens; R. M. Bukowski; W. J. Stuckey; J. D. McCracken; R. G. Gagliano; D. E. Lehane; R. P. Pugh

High-dose chlorozotocin in lung cancer: A southwest oncology group phase II study

C. D. Haas, R. L. Stephens, R. M. Bukowski, W. J. Stuckey, J. D. McCracken, R. G. Gagliano, D. E. Lehane, R. P. Pugh

Department of Medicine

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Abstract

Chlorozotocin was administered as an iv bolus at a dose of 200-225 mg/m² every 6 weeks for good-risk patients (100 mg/m² for poor-risk patients) with lung cancer. Only three of 71 fully evaluable patients responded; 12 had stable disease. Myelosuppression was acceptable and no other dose-limiting toxic effects were reported. Chlorozotocin is inactive in non-small cell lung cancer.

Original language	English (US)
Pages (from-to)	705-707
Number of pages	3
Journal	Cancer Treatment Reports
Volume	67
Issue number	7-8
State	Published - 1983

ASJC Scopus subject areas

Oncology
Cancer Research

Cite this

@article{15611433a4fe480cb4b65f6529106d66,

title = "High-dose chlorozotocin in lung cancer: A southwest oncology group phase II study",

abstract = "Chlorozotocin was administered as an iv bolus at a dose of 200-225 mg/m2 every 6 weeks for good-risk patients (100 mg/m2 for poor-risk patients) with lung cancer. Only three of 71 fully evaluable patients responded; 12 had stable disease. Myelosuppression was acceptable and no other dose-limiting toxic effects were reported. Chlorozotocin is inactive in non-small cell lung cancer.",

author = "Haas, {C. D.} and Stephens, {R. L.} and Bukowski, {R. M.} and Stuckey, {W. J.} and McCracken, {J. D.} and Gagliano, {R. G.} and Lehane, {D. E.} and Pugh, {R. P.}",

year = "1983",

language = "English (US)",

volume = "67",

pages = "705--707",

journal = "Cancer Treatment Reports",

issn = "0361-5960",

publisher = "U.S. National Cancer Institute",

number = "7-8",

}

TY - JOUR

T1 - High-dose chlorozotocin in lung cancer

T2 - A southwest oncology group phase II study

AU - Haas, C. D.

AU - Stephens, R. L.

AU - Bukowski, R. M.

AU - Stuckey, W. J.

AU - McCracken, J. D.

AU - Gagliano, R. G.

AU - Lehane, D. E.

AU - Pugh, R. P.

PY - 1983

Y1 - 1983

N2 - Chlorozotocin was administered as an iv bolus at a dose of 200-225 mg/m2 every 6 weeks for good-risk patients (100 mg/m2 for poor-risk patients) with lung cancer. Only three of 71 fully evaluable patients responded; 12 had stable disease. Myelosuppression was acceptable and no other dose-limiting toxic effects were reported. Chlorozotocin is inactive in non-small cell lung cancer.

AB - Chlorozotocin was administered as an iv bolus at a dose of 200-225 mg/m2 every 6 weeks for good-risk patients (100 mg/m2 for poor-risk patients) with lung cancer. Only three of 71 fully evaluable patients responded; 12 had stable disease. Myelosuppression was acceptable and no other dose-limiting toxic effects were reported. Chlorozotocin is inactive in non-small cell lung cancer.

UR - http://www.scopus.com/inward/record.url?scp=0020572576&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020572576&partnerID=8YFLogxK

M3 - Article

C2 - 6223694

AN - SCOPUS:0020572576

SN - 0361-5960

VL - 67

SP - 705

EP - 707

JO - Cancer Treatment Reports

JF - Cancer Treatment Reports

IS - 7-8

ER -

High-dose chlorozotocin in lung cancer: A southwest oncology group phase II study

Abstract

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this